Epigenomic Modulators and Thyroid Hormone Receptor β Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer

Area of Science:

• Molecular Biology
• Cancer Research
• Endocrinology

Background:

• Thyroid hormone receptor beta (TRβ) is a tumor suppressor involved in regulating gene expression.
• Aggressive thyroid cancers exhibit aberrant epigenomic signaling, chromatin accessibility, and gene expression.
• Effective treatments for advanced and resistant thyroid cancers are lacking.

Purpose of the Study:

• To review novel findings on the epigenomic landscape of TRβ in thyroid malignancy.
• To identify TRβ interactors and map functional protein communities.
• To explore therapeutic strategies targeting TRβ interactors for thyroid cancer treatment.

Main Methods:

• Review of recent studies on TRβ signaling in thyroid cancer.
• Identification of TRβ interactors and their functional protein communities.
• Exploration of combination therapies involving TRβ agonists and epigenetic enzyme inhibitors.

Main Results:

• Novel TRβ interactors in thyroid cells were identified.
• Nine distinct functional protein communities within the TRβ interactome were mapped.
• Synergistic effects of targeting TRβ interactors with epigenetic inhibitors and TRβ agonists were explored.

Conclusions:

• Understanding TRβ's epigenomic role is crucial for blocking thyroid tumor progression.
• Targeting TRβ interactors presents potential novel therapeutic avenues for thyroid cancer.
• Combination therapy with epigenetic inhibitors and TRβ agonists may reprogram tumor epigenetics and suppress oncogenic programs.